Jeffrey Anderson

Summary

Affiliation: LDS Hospital
Country: USA

Publications

  1. ncbi request reprint Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
    Am J Cardiol 99:169-74. 2007
  2. ncbi request reprint Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Am Heart J 153:67-73. 2007
  3. ncbi request reprint Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Intermountain Healthcare, Salt Lake City, UT, USA
    Circulation 116:2563-70. 2007
  4. doi request reprint Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, University of Utah, 325 8th Avenue, Salt Lake City, UT 84143, USA
    Am J Cardiol 101:23F-33F. 2008
  5. ncbi request reprint Progress in unraveling the genetics of coronary artery disease and myocardial infarction
    Jeffrey L Anderson
    Department of Cardiology, LDS Hospital, Salt Lake City, UT 84143, USA
    Curr Atheroscler Rep 9:179-86. 2007
  6. ncbi request reprint Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease
    Bryant M Whiting
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Am Heart J 150:243-50. 2005
  7. ncbi request reprint Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes
    Matthew J Kolek
    Cardiovascular Department, Division of Cardiology, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 148:1034-40. 2004
  8. pmc Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease
    Benjamin D Horne
    Cardiovascular Department, Intermountain Medical Center, Murray, UT 84157, USA
    Circ Cardiovasc Genet 1:85-92. 2008
  9. doi request reprint Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility
    Jeffrey L Anderson
    Cardiovascular Department, Intermountain Medical Center, Murray, UT 84107, USA
    Am Heart J 156:1155-1162.e2. 2008
  10. ncbi request reprint Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
    John F Carlquist
    Department of Medicine, Division of Cardiology, University of Utah School of Medicine, Cardiovascular Department, LDS Hospital, Salt Lake City, Utah, USA
    J Thromb Thrombolysis 22:191-7. 2006

Research Grants

  1. Risk Burden of Lipoprotein Metabolic Gene Haplotypes
    Jeffrey Anderson; Fiscal Year: 2007

Detail Information

Publications79

  1. ncbi request reprint Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, and University of Utah, Salt Lake City, Utah, USA
    Am J Cardiol 99:169-74. 2007
    ..A total CBC score is an important new addition to risk prediction, and it can be easily generated by computer for clinical use at negligible incremental cost...
  2. ncbi request reprint Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Am Heart J 153:67-73. 2007
    ....
  3. ncbi request reprint Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Intermountain Healthcare, Salt Lake City, UT, USA
    Circulation 116:2563-70. 2007
    ..Pharmacogenetic-guided dosing of warfarin is a promising application of "personalized medicine" but has not been adequately tested in randomized trials...
  4. doi request reprint Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, University of Utah, 325 8th Avenue, Salt Lake City, UT 84143, USA
    Am J Cardiol 101:23F-33F. 2008
    ..02586 mmol/L) is now recommended as a reasonable therapeutic goal...
  5. ncbi request reprint Progress in unraveling the genetics of coronary artery disease and myocardial infarction
    Jeffrey L Anderson
    Department of Cardiology, LDS Hospital, Salt Lake City, UT 84143, USA
    Curr Atheroscler Rep 9:179-86. 2007
    ..Despite the complexity of coronary heart disease genetics, steady progress can be expected...
  6. ncbi request reprint Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease
    Bryant M Whiting
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Am Heart J 150:243-50. 2005
    ..Moderate-sized studies have suggested that variants of candidate genes can influence laboratory markers of coronary artery disease (CAD), but whether they predict parallel changes in clinical CAD risk is unknown...
  7. ncbi request reprint Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes
    Matthew J Kolek
    Cardiovascular Department, Division of Cardiology, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 148:1034-40. 2004
    ..We evaluated whether the Asp299Gly polymorphism in the TLR4 gene, which impairs inflammatory responses, is associated with reduced vascular inflammation (assessed by C-reactive protein [CRP]) and a decreased risk for CAD and diabetes...
  8. pmc Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease
    Benjamin D Horne
    Cardiovascular Department, Intermountain Medical Center, Murray, UT 84157, USA
    Circ Cardiovasc Genet 1:85-92. 2008
    ..Using angiographic coronary artery disease (CAD) phenotyping, this study evaluated whether 9p21 single-nucleotide polymorphisms predict ischemic events (eg, myocardial infarction [MI]) among CAD patients...
  9. doi request reprint Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility
    Jeffrey L Anderson
    Cardiovascular Department, Intermountain Medical Center, Murray, UT 84107, USA
    Am Heart J 156:1155-1162.e2. 2008
    ..Variants at the 9p21 locus have been associated with coronary heart disease, but their precise disease phenotype and utility for clinical risk assessment are uncertain...
  10. ncbi request reprint Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
    John F Carlquist
    Department of Medicine, Division of Cardiology, University of Utah School of Medicine, Cardiovascular Department, LDS Hospital, Salt Lake City, Utah, USA
    J Thromb Thrombolysis 22:191-7. 2006
    ..vitamin K epoxide reductase complex subunit 1-VKORC1). We hypothesized that variants in these two genes explain a substantial proportion of variability in stable warfarin dose and could be used as a basis for improved dosing algorithms...
  11. doi request reprint Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)
    Heidi T May
    Intermountain Medical Center and LDS Hospital, Salt Lake City, Utah, USA
    Am J Cardiol 101:486-9. 2008
    ..In conclusion, in this trial of mixed dyslipidemic patients with diabetes, combination therapy was more effective in changing a variety of other cardiovascular risk markers...
  12. ncbi request reprint The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease
    John F Carlquist
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 146:1007-14. 2003
    ..We studied CETP Taq1B genotype, plasma HDL, and clinical events among all patients and patients stratified by statin treatment...
  13. ncbi request reprint The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure
    Matthew J Kolek
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    J Card Fail 11:677-83. 2005
    ..A common variant of the adenosine monophosphate deaminase (AMPD)-1 gene (C34T) results in enzymatic inactivity and may increase adenosine in cardiac muscle and confer cardioprotection through ischemic preconditioning...
  14. pmc Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography
    Benjamin D Horne
    Cardiovascular Department, Intermountain Medical Center, Murray, Utah, USA
    Am J Cardiol 102:814-819. 2008
    ..In conclusion, not only proscription of tobacco, but also routine periodic fasting was associated with lower risk of CAD...
  15. ncbi request reprint Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease
    Lillian L C Khor
    Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA
    Am J Med 117:657-64. 2004
    ..To determine whether sex and age affect serum C-reactive protein level and its prognostic value in patients with coronary artery disease...
  16. ncbi request reprint Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction
    James S Zebrack
    University of Utah School of Medicine, Salt Lake City, Utah 84132 2401, USA
    Am J Cardiol 89:145-9. 2002
    ....
  17. ncbi request reprint Associations with myocardial infarction of six polymorphisms selected from a three-stage genome-wide association study
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Intermountain Medical Center, Salt Lake City, UT 84143, USA
    Am Heart J 154:969-75. 2007
    ..In an independent but demographically similar population, this study tested 6 SNPs that were previously reported to be associated with MI...
  18. ncbi request reprint The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study
    Joseph B Muhlestein
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    J Am Coll Cardiol 48:396-401. 2006
    ..The primary objective was to determine the effect of statin-fibrate combination therapy on inflammatory biomarkers in patients with diabetes...
  19. ncbi request reprint Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing
    Kent G Meredith
    Cardiovascular Department, LDS Hospital, Division of Cardiology, University of Utah, Salt Lake City, Utah, USA
    Am J Cardiol 99:149-53. 2007
    ..In conclusion, this randomized trial in patients with chronic stable coronary artery disease showed a strong dose response for simvastatin for total and low-density lipoprotein cholesterol lowering but not for hs-CRP...
  20. ncbi request reprint Multiple less common genetic variants explain the association of the cholesteryl ester transfer protein gene with coronary artery disease
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Intermountain Medical Center, University of Utah, Salt Lake City, Utah 84143, USA
    J Am Coll Cardiol 49:2053-60. 2007
    ....
  21. pmc Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease
    Jeffrey L Anderson
    Cardiovascular Department, Intermountain Medical Center, Murray, UT 84107, USA
    Am Heart J 160:250-256.e3. 2010
    ....
  22. doi request reprint Exceptional mortality prediction by risk scores from common laboratory tests
    Benjamin D Horne
    Cardiovascular Department, Intermountain Medical Center, Murray, Utah 84157, USA
    Am J Med 122:550-8. 2009
    ..Many of their components are not commonly used, but they might contain independent risk information. This study tested the ability of a risk score combining all components to predict all-cause mortality...
  23. doi request reprint Incremental survival benefit with adherence to standardized heart failure core measures: a performance evaluation study of 2958 patients
    Abdallah G Kfoury
    Heart Failure Prevention and Treatment Program, Intermountain Medical Center and Intermountain Healthcare, 5121 S Cottonwood Street, Murray, UT 84107, USA
    J Card Fail 14:95-102. 2008
    ..Although adherence to these HF care processes may be improving, their collective impact on survival is not yet settled...
  24. pmc Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Intermountain Medical Center, Salt Lake City, UT 84143, USA
    Am Heart J 154:751-8. 2007
    ..Furthermore, differentiation of predictive ability by end point (MI vs CAD) has not been addressed. This study evaluated the association with MI of SNPs in genes encoding MMPs 1, 2, 3, and 9 and TIMPs 1, 2, and 3...
  25. ncbi request reprint Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target
    John F Carlquist
    LDS Hospital, Cardiology Department, 8th Avenue and C Street, Salt Lake City, UT 84143, USA
    Expert Rev Mol Diagn 7:511-7. 2007
    ..Considering the large number of biomarkers currently under evaluation, it is probable that useful additions to existing risk models may be found in combinatorial models...
  26. pmc Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography
    Matthew T Rondina
    Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Cardiology 109:196-201. 2008
    ..We evaluated sCD40L levels and future cardiovascular events in patients not experiencing ACS...
  27. ncbi request reprint Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing
    John F Carlquist
    Department of Internal Medicine, Division of Cardiology, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Thromb Thrombolysis 26:1-7. 2008
    ..99. Combined with a method for rapid buccal swab DNA extraction, genotyping results were obtained in a median of 59 min. These methods should facilitate genotype-driven warfarin dosing in "real-time" clinical practice...
  28. ncbi request reprint Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis
    John Carlquist
    Department of Internal Medicine, Division of Cardiology, University of Utah School of Medicine, Cardiovascular Department, LDS Hospital, Intermountain Healthcare, Salt Lake City, Utah 84143, USA
    Curr Opin Cardiol 22:352-8. 2007
    ..Genetic variants within this network can increase plasma HDL, but not with uniformly beneficial clinical outcomes. The purpose of this review is to explore and propose mechanisms for these discrepant observations...
  29. ncbi request reprint Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment
    Jessica L Clarke
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am J Cardiol 95:155-8. 2005
    ..This suggests that the conclusions of previous studies performed using the medium-sensitivity assay are still valid but that cross-study comparisons should use percentile rank...
  30. ncbi request reprint Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention
    Joseph B Muhlestein
    LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 146:351-8. 2003
    ..Diabetes mellitus (DM) is predictive of increased mortality for patients with coronary artery disease (CAD). To what extent this risk extends below the diabetic threshold (fasting glucose level [FG] <126 mg/dL) is uncertain...
  31. ncbi request reprint Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice
    James S Zebrack
    University of Utah School of Medicine, Department of Internal Medicine, Division of Cardiology, Salt Lake City, UT, USA
    Prog Cardiovasc Nurs 17:174-85. 2002
    ..Finally, the authors summarize future expectations for assessing and modulating the vascular inflammation to inhibit initiation and progression of the atherosclerotic process...
  32. ncbi request reprint C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina
    James S Zebrack
    Division of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    J Am Coll Cardiol 39:632-7. 2002
    ..The objective of this study was to determine the prognostic value of C-reactive protein (CRP) independent of coronary angiographic findings...
  33. ncbi request reprint Less affluent area of residence and lesser-insured status predict an increased risk of death or myocardial infarction after angiographic diagnosis of coronary disease
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Ann Epidemiol 14:143-50. 2004
    ..Low socioeconomic status (SES) predicts coronary artery disease (CAD) onset, but its value among patients with CAD is uncertain. Geographic measures (e.g., residential neighborhood) may predict risk, but this requires further evaluation...
  34. doi request reprint Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease
    Joseph B Muhlestein
    Intermountain Medical Center, Murray, Utah University of Utah, Salt Lake City, Utah, USA
    Am J Cardiol 106:764-9. 2010
    ..In conclusion, elevated baseline PRA is associated with cardiac morbidity and mortality in patients with coronary artery disease but normal left ventricular function and no previous MI or HF...
  35. ncbi request reprint C-reactive protein predicts death in patients with non-ischemic cardiomyopathy
    Brianna S Ronnow
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Cardiology 104:196-201. 2005
    ..0) significantly and independently predicted mortality. Even in the absence of coronary artery disease, patients with left ventricular dysfunction are at increased risk of mortality based on their baseline CRP concentrations...
  36. ncbi request reprint A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction
    Yoshikazu Yazaki
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    J Card Fail 10:316-20. 2004
    ..This variant might lead to ischemic preconditioning by increasing tissue adenosine. We tested whether the survival benefit of C34T occurs preferentially in the setting of ischemic left ventricular dysfunction...
  37. ncbi request reprint Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Circulation 107:258-63. 2003
    ..This study prospectively evaluated the effect of statins on CMV-and CRP-associated death among patients with significant, angiographically defined CAD...
  38. ncbi request reprint Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital and University of Utah, Salt Lake City, Utah, USA
    Cardiology 101:185-93. 2004
    ..The prevalence of the metabolic syndrome (MS) is growing. The Adult Treatment Panel (ATP) III provided a uniform definition of MS but no information on its predictive ability...
  39. pmc Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study
    Paul N Hopkins
    Cardiovascular Genetics Research, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Atherosclerosis 207:559-66. 2009
    ..30 with TG>150mg/dL) indicative of atherogenic remnant accumulation (type III hyperlipidemia). However, virtually no reports are available which examine potential associations between CAD and VLDL-C/TG at the lower end of the spectrum...
  40. ncbi request reprint Which white blood cell subtypes predict increased cardiovascular risk?
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    J Am Coll Cardiol 45:1638-43. 2005
    ..We sought to determine the predictive ability of total white blood cell (WBC) count and its subtypes for risk of death or myocardial infarction (MI)...
  41. doi request reprint Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study
    Jeffrey L Anderson
    Cardiovascular Department, Intermountain Medical Center, Murray, Utah 84107, USA
    J Cardiovasc Pharmacol Ther 14:170-5. 2009
    ..This large epidemiologic study failed to confirm a reported large event differential for tegaserod that was noted incidentally in a clinical trials database, suggesting that the prior observation may have been due to chance...
  42. ncbi request reprint Frequency of elevation of C-reactive protein in atrial fibrillation
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, University of Utah, Salt Lake City 84143, USA
    Am J Cardiol 94:1255-9. 2004
    ..Increased CRP is a new risk marker for AF propensity, and testing therapies that target inflammation should be considered...
  43. ncbi request reprint Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death
    Heidi T May
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Am Heart J 152:997-1003. 2006
    ..We evaluated the independent association of lipoprotein-associated phospholipase A2 (Lp-PLA2) to angiographic CAD and CV events adjusting for standard factors, lipids, and CRP...
  44. ncbi request reprint Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients
    Chloe A Allen Maycock
    Cardiology Research, LDS Hospital, 8th Avenue and C Street, Salt Lake City, Utah 84143, USA
    J Am Coll Cardiol 40:1777-85. 2002
    ..This study evaluated the effect of statin therapy on mortality in individuals with significant coronary artery disease (CAD) stratified by age...
  45. ncbi request reprint Failure of benefit and early hazard of bucindolol for Class IV heart failure
    Jeffrey L Anderson
    Division of Cardiology, LDS Hospital, University of Utah, Salt Lake City 84143, USA
    J Card Fail 9:266-77. 2003
    ..The risks and benefits of beta-blockade with bucindolol were assessed in heart failure (HF) patients with Class IV symptoms within the Beta-blocker Evaluation of Survival Trial (BEST)...
  46. ncbi request reprint Cardiovascular pharmacogenomics: current status, future prospects
    Jeffrey L Anderson
    Intermountain Heart Collaborative Research Group, LDS Hospital Cardiovascular Department, and University of Utah School of Medicine, Salt Lake City, Utah 84143, USA
    J Cardiovasc Pharmacol Ther 8:71-83. 2003
    ..Rapid research progress and initial clinical applications with pharmacogenomics are foreseen in the near future...
  47. ncbi request reprint Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay
    Thomas B Martins
    Associated Regional and University Pathologists ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 84108, USA
    Am J Clin Pathol 125:906-13. 2006
    ..017), and CRP (P pound .001). Cytokine profiles may have a role in differentiating patients with CAD with MI from those with chest pain due to other disorders and in deciphering the role of inflammation in the pathogenesis of CAD...
  48. ncbi request reprint Effect of implementation of folic acid fortification of food on homocysteine concentrations in subjects with coronary artery disease
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, and University of Utah School of Medicine, Salt Lake City, Utah 84143, USA
    Am J Cardiol 90:536-9. 2002
  49. ncbi request reprint High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene
    Benjamin D Horne
    Cardiovascular Department, LDS Hospital, Salt Lake City, UT 84143, USA
    Ann Hum Genet 70:524-34. 2006
    ..This study provides an optimal set of tSNPs for association analyses of CETP. The observed complexity of LD structure highlights the importance of using methods, such as PCA, that allow for multiple dynamics in intragenic LD structure...
  50. ncbi request reprint Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment
    T Jared Bunch
    Cardiovascular Department, LDS Hospital and University of Utah, Salt Lake City 84143, USA
    Am J Cardiol 90:299-302. 2002
  51. ncbi request reprint Early effects of statins in patients with coronary artery disease and high C-reactive protein
    Joseph B Muhlestein
    Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am J Cardiol 94:1107-12. 2004
    ..This provides further evidence of an anti-inflammatory effect of statins...
  52. doi request reprint Risk of nephropathy is not increased by the administration of larger volume of contrast during coronary angiography
    Troy E Madsen
    Division of Emergency Medicine, University of Utah, Salt Lake City, UT, USA
    Crit Pathw Cardiol 8:167-71. 2009
    ..The apparent inverse relation of risk with volume in the overall population is likely explained by clinical practice bias. If confirmed, these results may have important clinical implications...
  53. doi request reprint Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies
    Megan B Smith
    Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, Utah, USA
    Cardiology 116:61-9. 2010
    ..Multiple factors influence warfarin metabolism and can significantly affect the risk of adverse events. The extent to which patients understand the modifiable factors that impact on warfarin safety and efficacy is unclear...
  54. ncbi request reprint Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry
    Tami L Bair
    Cardiovascular Department, University of Utah, Salt Lake City, USA
    Circulation 116:I226-31. 2007
    ..In this study, we examined the outcomes of major adverse cardiovascular events and death for subgroups of typical "real-world" patients undergoing coronary revascularization in the modern era...
  55. doi request reprint Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure
    Robert Kevin Rogers
    University of Utah, Salt Lake City, 84132 2401, USA
    Am Heart J 158:777-83. 2009
    ..B-type natriuretic peptide (BNP) correlates with left ventricular (LV) end-diastolic pressure (LVEDP) and predicts cardiovascular events. We sought to determine whether BNP has prognostic value independent of LVEDP...
  56. ncbi request reprint Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention
    Benjamin D Horne
    LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 144:491-500. 2002
    ....
  57. ncbi request reprint Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide
    Heidi T May
    LDS Hospital, Intermountain Medical Center, Salt Lake City, Utah, USA
    Am J Cardiol 100:697-700. 2007
    ..02). In conclusion, the SHFM predicts survival in patients with HF in a hospital-based population, with areas under the curve similar to those from data on which models were initially fit...
  58. ncbi request reprint The role of infection in the pathogenesis of cardiovascular disease
    James S Zebrack
    Department of Internal Medicine, Division of Cardiology, University of Utah School of Medicine, c o LDS Hospital, Eighth Avenue and C Street, Salt Lake City, UT 84143, USA
    Prog Cardiovasc Nurs 18:42-9. 2003
    ..This manuscript summarizes current understanding of the role of infectious agents as a trigger of inflammation, as a contributor to atherosclerosis, and the potential role of antibiotic therapy in the treatment of atherosclerosis...
  59. ncbi request reprint Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program
    Jason M Lappe
    Intermountain Health Care, LDS Hospital, Salt Lake City, Utah 84143, USA
    Ann Intern Med 141:446-53. 2004
    ..Despite recent advances in the treatment and prevention of cardiovascular disease, a treatment gap for secondary prevention medications still exists...
  60. ncbi request reprint Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients
    Joseph B Muhlestein
    Division of Cardiology, Department of Cardiovascular Medicine, LDS Hospital, Salt Lake City, Utah 84143, USA
    Am Heart J 150:182-7. 2005
    ..However, few studies have had a sufficient sample size or adequate follow-up to determine whether this advantage results in a positive effect on mortality...
  61. ncbi request reprint Do statins increase the risk of idiopathic polyneuropathy?
    Jeffrey L Anderson
    Cardiovascular Department, LDS Hospital, Cardiology Division, Intermountain Health Care, Salt Lake City, Utah 84143, USA
    Am J Cardiol 95:1097-9. 2005
    ..It was found that statin use before diagnosis was not significantly greater in patients than controls (odds ratio 1.30, 95% confidence interval 0.3 to 2.1, p = 0.27), nor were doses different between patients and controls...
  62. pmc Antibiotic trials for coronary heart disease
    Jeffrey L Anderson
    University of Utah School of Medicine, Cardiovascular Department, LDS Hospital, Salt Lake City, Utah 84143, USA
    Tex Heart Inst J 31:33-8. 2004
    ..New and innovative experimental approaches, in addition to traditionally designed antibiotic trials, should be welcome in our attempts to gain adequate insight into the role of infection in atherosclerosis and its therapy...
  63. ncbi request reprint The role of inflammation and infection in the pathogenesis and evolution of coronary artery disease
    James S Zebrack
    University of Utah School of Medicine, Department of Internal Medicine, Division of Cardiology, 30 North 1900 East, 4N100, Salt Lake City 84132 2401, USA
    Curr Cardiol Rep 4:278-88. 2002
    ..Whether antibiotics or vaccines will be useful in CAD prevention remains to be shown. Meanwhile, therapies with proven vascular anti-inflammatory effects (eg, diet, exercise, smoking cessation, aspirin, statins) should be optimized...
  64. ncbi request reprint Infection, antibiotics, and atherothrombosis--end of the road or new beginnings?
    Jeffrey L Anderson
    N Engl J Med 352:1706-9. 2005
  65. ncbi request reprint Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure
    T Jared Bunch
    Mayo Clinic Foundation, Rochester, Minnesota, USA
    Am J Cardiol 95:827-31. 2005
    ..No effect was observed on longitudinal incidence of AMI or the combination of death/nonfatal MI...
  66. ncbi request reprint Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease
    Troy E Madsen
    Ohio State University Medical Center, Columbus, OH 43210, USA
    Am J Nephrol 25:45-9. 2005
    ..This study prospectively evaluated the predictive value of serum uric acid (SUA) levels for mortality after angiographic diagnosis of CAD...
  67. ncbi request reprint Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death
    Jianhui Zhu
    Cardiovascular Research Institute of the MedStar Research Institute, Washington Hospital Center, Washington, DC 20010, USA
    Am J Cardiol 89:155-8. 2002
    ..pylori seropositivity was 1.12 (95% confidence interval 0.81 to 1.54). Our data suggest that prior infection with H. pylori is not a major factor determining either risk of CAD, AMI, or death in patients with CAD...
  68. ncbi request reprint CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group
    Sidney C Smith
    Circulation 110:e550-3. 2004
  69. doi request reprint Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol
    Amy J Sehnert
    CardioDx, Inc, Palo Alto, California 94303, USA
    J Am Coll Cardiol 52:644-51. 2008
    ..This study investigated the role of adrenergic receptor genetics on transplant-free survival in heart failure (HF)...
  70. ncbi request reprint Genetic polymorphisms of hepatic lipase and cholesteryl ester transfer protein, intermediate phenotypes, and coronary risk: do they add up yet?
    Jeffrey L Anderson
    J Am Coll Cardiol 41:1990-3. 2003
  71. ncbi request reprint Restenosis after coronary intervention: narrowing C-reactive protein's prognostic potential?
    Jeffrey L Anderson
    Am J Med 115:147-9. 2003
  72. ncbi request reprint ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  73. ncbi request reprint Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
    Thomas A Pearson
    Circulation 107:499-511. 2003
  74. ncbi request reprint Should C-reactive protein be measured routinely during acute myocardial infarction?
    James S Zebrack
    Am J Med 115:735-7. 2003
  75. ncbi request reprint Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution
    C Arden Pope
    Brigham Young University, Provo, UT 84602 2363, USA
    Circulation 114:2443-8. 2006
    ..These findings are inconclusive and controversial and require further study. This study evaluates the role of short-term particulate exposure in triggering acute ischemic heart disease events...
  76. pmc A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure
    Stephen B Liggett
    Department of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 103:11288-93. 2006
    ..We conclude that beta(1)AR-389 variation alters signaling in multiple models and affects the beta-blocker therapeutic response in HF and, thus, might be used to individualize treatment of the syndrome...
  77. ncbi request reprint ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999
    Elliott M Antman
    Circulation 110:588-636. 2004
  78. doi request reprint Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines
    Michael H Davidson
    Preventive Cardiology Center, Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:51F-57F. 2008
    ..However, at this time Lp-PLA(2) cannot be recommended as a target of therapy...
  79. pmc Sodium channel mutations and susceptibility to heart failure and atrial fibrillation
    Timothy M Olson
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 293:447-54. 2005
    ..Recently, genetic defects in calcium and potassium regulation have been discovered in patients with DCM, implicating an alternative disease mechanism. The full spectrum of genetic defects in DCM, however, has not been established...

Research Grants4

  1. Risk Burden of Lipoprotein Metabolic Gene Haplotypes
    Jeffrey Anderson; Fiscal Year: 2007
    ..We believe this thorough, novel approach will lead to a major advance in genetic CHD risk assessment, enabling the vision of gene-based medicine for CHD to be realized. ..